In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients

BACKGROUND: We sought to determine the predictive value of in situ mRNA measurement compared to traditional methods on a cohort of trastuzumab-treated metastatic breast cancer patients. METHODS: A tissue microarray composed of 149, classified as HER2-positive, metastatic breast cancers treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Vassilakopoulou, Maria, Togun, Taiwo, Dafni, Urania, Cheng, Huan, Bordeaux, Jennifer, Neumeister, Veronique M., Bobos, Mattheos, Pentheroudakis, George, Skarlos, Dimosthenis V., Pectasides, Dimitrios, Kotoula, Vassiliki, Fountzilas, George, Rimm, David L., Psyrri, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072595/
https://www.ncbi.nlm.nih.gov/pubmed/24968015
http://dx.doi.org/10.1371/journal.pone.0099131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072595/
https://www.ncbi.nlm.nih.gov/pubmed/24968015
http://dx.doi.org/10.1371/journal.pone.0099131

Ejemplares similares